Zdrowie i gospodarka · 15/02/2012

FDA Releases Draft Guidance on Biosimilarity

The Food and Drug Administration (FDA) has made available a draft guidance document to help pharmaceutical companies demonstrate that their proposed biosimilar therapies are comparable to existing reference products, paving the way for faster approval through an abbreviated licensure pathway.